NASDAQ:AKRO

Akero Therapeutics Competitors

$26.72
-0.61 (-2.23 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.07
$27.40
50-Day Range
$26.37
$34.19
52-Week Range
$19.58
$41.16
Volume151,259 shs
Average Volume281,435 shs
Market Capitalization$930.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58

Competitors

Akero Therapeutics (NASDAQ:AKRO) Vs. HCM, APLS, NKTR, ALKS, ACAD, and KRTX

Should you be buying AKRO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Akero Therapeutics, including Hutchison China MediTech (HCM), Apellis Pharmaceuticals (APLS), Nektar Therapeutics (NKTR), Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), and Karuna Therapeutics (KRTX).

Akero Therapeutics (NASDAQ:AKRO) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares Akero Therapeutics and Hutchison China MediTech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21
Hutchison China MediTech$204.89 million18.16$-106,020,000.00($0.80)-31.24

Akero Therapeutics has higher earnings, but lower revenue than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akero Therapeutics and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akero TherapeuticsN/A-40.84%-38.33%
Hutchison China MediTechN/AN/AN/A

Institutional & Insider Ownership

83.5% of Akero Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Akero Therapeutics and Hutchison China MediTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akero Therapeutics00703.00
Hutchison China MediTech00203.00

Akero Therapeutics currently has a consensus price target of $57.2857, suggesting a potential upside of 114.39%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 60.06%. Given Akero Therapeutics' higher possible upside, equities research analysts clearly believe Akero Therapeutics is more favorable than Hutchison China MediTech.

Volatility and Risk

Akero Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Summary

Akero Therapeutics beats Hutchison China MediTech on 6 of the 11 factors compared between the two stocks.

Akero Therapeutics (NASDAQ:AKRO) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Akero Therapeutics and Apellis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.73

Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.5% of Akero Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are held by institutional investors. 7.1% of Akero Therapeutics shares are held by insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Akero Therapeutics and Apellis Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akero Therapeutics00703.00
Apellis Pharmaceuticals031112.87

Akero Therapeutics currently has a consensus price target of $57.2857, suggesting a potential upside of 114.39%. Apellis Pharmaceuticals has a consensus price target of $130.0769, suggesting a potential upside of 188.10%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Akero Therapeutics.

Volatility & Risk

Akero Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Akero Therapeutics and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akero TherapeuticsN/A-40.84%-38.33%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Nektar Therapeutics (NASDAQ:NKTR) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

95.3% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are owned by institutional investors. 3.0% of Nektar Therapeutics shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Nektar Therapeutics and Akero Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million31.38$-440,670,000.00($2.52)-7.83
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21

Akero Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nektar Therapeutics and Akero Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics16102.00
Akero Therapeutics00703.00

Nektar Therapeutics currently has a consensus price target of $25.1429, indicating a potential upside of 27.43%. Akero Therapeutics has a consensus price target of $57.2857, indicating a potential upside of 114.39%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Nektar Therapeutics.

Profitability

This table compares Nektar Therapeutics and Akero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-269.05%-30.74%-22.63%
Akero TherapeuticsN/A-40.84%-38.33%

Volatility and Risk

Nektar Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Summary

Nektar Therapeutics beats Akero Therapeutics on 7 of the 13 factors compared between the two stocks.

Akero Therapeutics (NASDAQ:AKRO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Institutional and Insider Ownership

83.5% of Akero Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Alkermes shares are held by institutional investors. 7.1% of Akero Therapeutics shares are held by insiders. Comparatively, 4.5% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Akero Therapeutics and Alkermes' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akero TherapeuticsN/A-40.84%-38.33%
Alkermes-6.28%9.35%5.50%

Analyst Ratings

This is a summary of recent ratings and price targets for Akero Therapeutics and Alkermes, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akero Therapeutics00703.00
Alkermes14102.00

Akero Therapeutics currently has a consensus target price of $57.2857, indicating a potential upside of 114.39%. Alkermes has a consensus target price of $22.00, indicating a potential upside of 1.64%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Akero Therapeutics is more favorable than Alkermes.

Risk and Volatility

Akero Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Valuation and Earnings

This table compares Akero Therapeutics and Alkermes' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21
Alkermes$1.17 billion2.97$-196,620,000.00$0.07309.21

Akero Therapeutics has higher earnings, but lower revenue than Alkermes. Akero Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Akero Therapeutics beats Alkermes on 7 of the 13 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Risk & Volatility

ACADIA Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.

Profitability

This table compares ACADIA Pharmaceuticals and Akero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Akero TherapeuticsN/A-40.84%-38.33%

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Akero Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million9.93$-235,260,000.00($1.60)-13.14
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21

Akero Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for ACADIA Pharmaceuticals and Akero Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals012602.33
Akero Therapeutics00703.00

ACADIA Pharmaceuticals currently has a consensus price target of $31.4375, suggesting a potential upside of 49.56%. Akero Therapeutics has a consensus price target of $57.2857, suggesting a potential upside of 114.39%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than ACADIA Pharmaceuticals.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Akero Therapeutics on 8 of the 13 factors compared between the two stocks.

Karuna Therapeutics (NASDAQ:KRTX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Karuna Therapeutics and Akero Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karuna Therapeutics001103.00
Akero Therapeutics00703.00

Karuna Therapeutics currently has a consensus target price of $151.70, suggesting a potential upside of 35.74%. Akero Therapeutics has a consensus target price of $57.2857, suggesting a potential upside of 114.39%. Given Akero Therapeutics' higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Karuna Therapeutics.

Profitability

This table compares Karuna Therapeutics and Akero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karuna TherapeuticsN/A-13.91%-13.72%
Akero TherapeuticsN/A-40.84%-38.33%

Risk & Volatility

Karuna Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Insider and Institutional Ownership

74.8% of Karuna Therapeutics shares are held by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are held by institutional investors. 18.1% of Karuna Therapeutics shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Karuna Therapeutics and Akero Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-30.37
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.21

Karuna Therapeutics is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.


Akero Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$24.99-5.0%$3.72 billion$204.89 million-31.24
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.15-4.3%$3.63 billionN/A-6.08
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.73-1.9%$3.60 billion$114.62 million-7.96Earnings Announcement
Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$21.65-1.7%$3.47 billion$1.17 billion-47.05High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.02-0.2%$3.37 billion$339.08 million-12.22Earnings Announcement
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$111.76-2.8%$3.29 billionN/A-55.60Earnings Announcement
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$59.87-2.9%$3.21 billion$1.11 billion19.25
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$62.93-3.2%$3.09 billionN/A-17.93Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$84.76-0.4%$3.07 billion$26.52 million-7.47Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$61.39-3.6%$3.01 billion$42.98 million-23.98
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.97-2.6%$2.92 billion$60,000.00-11.17
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.60-2.5%$2.82 billion$644.77 million-10.50Upcoming Earnings
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.90-3.4%$2.74 billion$306.98 million-5.57Earnings Announcement
Insmed logo
INSM
Insmed
1.2$25.99-25.4%$2.68 billion$136.47 million-10.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$60.89-3.9%$2.68 billion$421.03 million21.44Analyst Report
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.35-1.0%$2.68 billionN/A-23.82Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.24-6.1%$2.66 billion$80.43 million96.39Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.39-3.8%$2.50 billion$182.24 million-8.17News Coverage
Gap Down
Cryoport logo
CYRX
Cryoport
1.7$54.44-15.8%$2.48 billion$33.94 million-93.86Earnings Announcement
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$61.71-5.3%$2.48 billionN/A0.00
Organogenesis logo
ORGO
Organogenesis
1.0$19.29-9.6%$2.47 billion$260.98 million-321.50Analyst Downgrade
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.62-1.0%$2.42 billionN/A0.00
OPKO Health logo
OPK
OPKO Health
1.9$3.54-7.4%$2.37 billion$901.90 million-19.64
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.83-1.6%$2.34 billion$963.01 million14.54Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$37.47-3.1%$2.33 billion$2.11 million-8.11Earnings Announcement
Analyst Revision
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.8$19.97-5.7%$2.33 billion$306.49 million22.44Earnings Announcement
Xencor logo
XNCR
Xencor
1.6$38.14-3.9%$2.22 billion$156.70 million-27.24Earnings Announcement
Analyst Report
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$131.87-1.1%$2.17 billionN/A-11.91Earnings Announcement
Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$126.66-3.1%$2.11 billion$120.28 million-127.94Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.66-2.0%$2.10 billionN/A-27.94Earnings Announcement
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$28.86-5.5%$2.05 billion$15 million-15.11Earnings Announcement
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$26.61-0.6%$2.05 billion$103.54 million-20.01Earnings Announcement
Analyst Downgrade
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$54.39-4.7%$2.04 billionN/A-20.22Gap Down
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.90-0.5%$1.98 billion$23.90 million-16.09Earnings Announcement
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.43-3.8%$1.96 billion$410,000.00-5.96News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.8$32.91-4.3%$1.91 billion$25 million-6.58Earnings Announcement
Analyst Revision
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.04-3.4%$1.84 billion$34.51 million-17.13Earnings Announcement
MacroGenics logo
MGNX
MacroGenics
1.4$30.47-4.4%$1.83 billion$64.19 million-9.73
Amarin logo
AMRN
Amarin
1.6$4.59-0.0%$1.81 billion$429.76 million-91.78
FibroGen logo
FGEN
FibroGen
1.8$19.42-4.2%$1.79 billion$256.58 million-7.44
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.99-0.2%$1.77 billion$428.41 million15.93Earnings Announcement
Morphic logo
MORF
Morphic
1.5$47.93-1.6%$1.74 billion$16.98 million-30.72Analyst Report
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$30.16-7.3%$1.71 billionN/A0.00
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.38-3.6%$1.67 billion$26.87 million-12.24Earnings Announcement
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.34-3.4%$1.67 billionN/A-6.53
Kura Oncology logo
KURA
Kura Oncology
1.6$24.74-5.7%$1.64 billionN/A-15.18Earnings Announcement
Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$32.55-4.9%$1.63 billionN/A-3.53Gap Up
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.63-8.6%$1.62 billionN/A0.00Upcoming Earnings
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.56-5.3%$1.61 billion$145.97 million-7.11Earnings Announcement
Upcoming Earnings
High Trading Volume
News Coverage
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.